Local Market Ecosystems Require Deeper Analytics to Understand Physician Behaviors
Over the past decade, the distribution model for medication delivery has evolved from retail pharmacies and mail order to Specialty Pharmacies (SP), 340B Contract Pharmacies, and Rare Disease Pharmacies. In addition, large health systems are continuing the trend of market consolidation by purchasing physician practices, smaller regional hospitals, long-term care facilities and other ancillary healthcare services. These health systems are using their size and influence to change the patient journey.
Gone are the good old days when the traditional Rx pathway involved a doctor writing a prescription that would be filled at the local pharmacy. Back then, it was easy to identify who wrote the prescription and where it was filled. The prescription could be assigned to the appropriate territory with a high degree of certainty.
Today’s Rx pathway, however, is significantly more complex. AMA Opt Out Physicians, the multi-layered process used by pharma to help a patient gain access to a drug by copay cards, free trial vouchers, HUB distribution models, SP pharmacy and 340B Contract pharmacy delivery, has made it extremely challenging to follow the patient journey. As a result, it has become increasingly more difficult for pharma to visualize the patient journey and gain access to high quality data and information for strategic decision making and planning.
Good news, there is a solution to these challenges. For nearly two decades, MSA Healthcare Data Management (HCDM) has been solving these and other data access problems for pharma. MSA’s patented, state-of-the-art technologies and process help pharma see an up to 360ﹾ view of the patient journey.
As the market leader, MSA HCDM offers pharma the most credentialed, most configurable, and most trusted HIPAA-compliant de-identification and matching solutions. The unparalleled service provided by MSA’s team of healthcare data management experts ensures the timely delivery of the highest quality data – the differentiating factor that many top Life Science companies rely on.
MSA’s structured methodology for integrating, protecting, and transforming disparate data from one or multiple sources into high-quality, longitudinally-aligned datasets leads to the actionable insights pharma requires to improve patient outcomes, reduce healthcare costs, and drive innovative research.
MSA’s Data@Factory links de-identified, MSA-provided Lab, Medical Claims, and EHR Clinical Data with other disparate data from one or more sources, providing a longitudinal anonymous patient-level database for sophisticated data analytics of the comprehensive patient journey.
As pharma continues to move away from national strategies and towards local market ecosystems, access to data and information is even more critical. Learn more about MSA HCDM. Reach out to Frank Salopek, Director Business Development at firstname.lastname@example.org. Visit us at https://hcdm.msa.com.